Each CLOPID® coated tablet contains Clopidogrel Bisulfate equivalent to Clopidogrel 75 mg


Pharmacology :

Clopidogrel is a prodrug, one of its metabolites is an inhibitor of platelet aggregation. Clopidogrel must be metabolized by CYP450 enzymes to produce an active metabolite that inhibits platelet aggregation. The active metabolite of Clopidogrel automatically inhibits adenosine diphosphate (ADP) to the platelet receptor P2Y12 and further inhibits ADP-mediated activation of the glycoa GPIIb/III complex, thereby inhibiting platelet aggregation. Due to being irreversible, the platelets will be affected during their lifetime (about 7-10 days) and the restoration of normal platelet function at a rate consistent with platelet turnover. Platelet aggregation induced by agonists other than ADP is also inhibited by inhibiting amplification of platelet activation by ADP-deleting. Because the active metabolites of Clopidogrel are formed by CYP450 enzymes, some of them are polymorphic or can be inhibited by other drugs, so not all patients will have adequate platelet inhibition.



Clopidogrel is indicated for the prevention of atherothrombotic secondary events in:

  • Patients suffering from myocardial infarction (from a few days to less than 35 days), ischemic stroke (from 7 days to less than 6 months) or peripheral artery disease
  • Patients suffering from acute coronary disease:
  • Acute coronary syndrome with non-ST-segment elevation (unstable angina or non-Q-wave myocardial infarction), including patients undergoing stent placement after percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA)
  • Acute myocardial infarction with ST segment elevation, in combination with ASA in medically treated patients eligible for thrombolytic therapy


Dosage and How to Use:


Adults and seniors

  • Acute coronary syndrome with non-ST-segment elevation (unstable angina or non-Q-wave myocardial infarction): Clopidogrel treatment should be started with a single loading dose of 300 mg and then continued at a dose of 75 mg once daily (with acetylsalicylic acid). ) (ASA) 75-325 mg/day). Because higher ASA doses carry a higher risk of bleeding, higher ASA doses should not exceed 100 mg. The optimal duration of treatment has not been formally established, but maximum benefit is seen within 3 months
  • Acute myocardial infarction with ST segment elevation: Clopidogrel should be given as a single daily dose of 75 mg starting with a loading dose of 300 mg in combination with ASA and with or without thrombolytics. For patients older than 75 years, Clopidogrel should be started without a loading dose. Combination therapy should be started as early as possible after initiation and continued for at least 4 weeks. The benefit of the combination of Clopidogrel with ASA over 4 weeks has not been studied in these conditions



How to use :

For oral use

Can be given with or without food


storage :

Store at a temperature below 30°C, avoid direct light


Packaging :

CLOPID® Film Coated Tablets     Box, 3 strips @ 10 seed-coated tablets       Reg Number. : DKL2108027217A1


Categorised in:

This post was written by admin